Growth Metrics

Ligand Pharmaceuticals (LGND) Debt to Equity (2016 - 2025)

Ligand Pharmaceuticals' Debt to Equity history spans 12 years, with the latest figure at $0.44 for Q4 2025.

  • For Q4 2025, Debt to Equity changed N/A year-over-year to $0.44; the TTM value through Dec 2025 reached $0.44, changed N/A, while the annual FY2025 figure was $0.44, N/A changed from the prior year.
  • Debt to Equity for Q4 2025 was $0.44 at Ligand Pharmaceuticals, down from $0.47 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.47 in Q3 2025 and bottomed at $0.09 in Q3 2022.
  • The 3-year median for Debt to Equity is $0.14 (2022), against an average of $0.23.